Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic diseases and inflammation for patients who have limited or no approved treatment options. Co.'s primary product is Andexxa, an antidote for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Bevyxxa is an anticoagulant approved for hospital and extended duration prophylaxis of venous thromboembolism in adult patients. Cerdulatinib is Co.'s investigational oral, dual spleen tyrosine kinase and janus kinase inhibitor. The PTLA average annual return since 2013 is shown above.
The Average Annual Return on the PTLA average annual return since 2013 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PTLA average annual return since 2013 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PTLA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|